HER2+ gastroesophageal adenocarcinomas: Current standards and therapeutic prospects (notice n° 498630)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01295cam a2200181 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121081700.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Quesada, Stanislas |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | HER2+ gastroesophageal adenocarcinomas: Current standards and therapeutic prospects |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2022.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 10 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Esogastric adenocarcinomas (EGAs) are characterized in 10–20% of cases by overexpression and/or amplification of HER2. Current standard treatment for HER2+ EGAs relies on trastuzumab (an anti-HER2 antibody) plus a doublet of chemotherapy (fluoropyrimidine + platinum salt). For more than a decade, no obvious therapeutic progress has enriched the therapeutic arsenal for these patients, whether in the first-line with other anti-HER2 agents or in the context of trastuzumab resistance. The first results of studies based on trastuzumab deruxtecan and immune checkpoint inhibitors are therefore likely to change management practices for HER2+ EGAs. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Adenis, Antoine |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Samalin, Emmanuelle |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 29 | 4 | 2022-04-01 | p. 507-513 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-hepato-gastro-oncologie-digestive-2022-4-page-507?lang=en&redirect-ssocas=7080">https://shs.cairn.info/journal-hepato-gastro-oncologie-digestive-2022-4-page-507?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux